A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)

被引：0
|
作者：
Zhang, X. [1 ]
Cui, J. [1 ]
Quan, M. [2 ]
Zhang, T. [3 ]
Cao, D. [4 ]
Li, Z. [5 ]
Yang, D. T. C. [6 ]
Zhu, X. [6 ]
Chen, Y. [6 ]
Liang, P. [6 ]
Yao, L. [6 ]
Wang, L. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Renji Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Tongji Univ, Dept Oncol, Shanghai East Oriental Hosp, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Oncol, Union Hosp Tongji Med Coll, Wuhan, Peoples R China
[4] Sichuan Univ, Abdominal Oncol, West China Hosp, Chengdu, Peoples R China
[5] Harbin Med Univ, Dept Oncol, Canc Hosp, Harbin, Peoples R China
[6] Abbisko Therapeut Co Ltd, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1533TiP
引用
收藏
页码：S934 / S935
页数：2
相关论文
共 50 条
  • [21] A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
    Ko, Andrew H.
    Bekaii-Saab, Tanios
    Van Ziffle, Jessica
    Mirzoeva, Olga M.
    Joseph, Nancy M.
    Talasaz, AmirAli
    Kuhn, Peter
    Tempero, Margaret A.
    Collisson, Eric A.
    Kelley, R. Kate
    Venook, Alan P.
    Dito, Elizabeth
    Ong, Anna
    Ziyeh, Sharvina
    Courtin, Ryan
    Linetskaya, Regina
    Tahiri, Sanaa
    Korn, W. Michael
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 61 - 68
  • [22] Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy
    Hohmann, Nicolas
    Sprick, Martin Ronald
    Ahmed, Azaz
    Burhenne, Juergen
    Kirchner, Marietta
    Le Cornet, Lucian
    Kratzmann, Markus
    Hajda, Jacek
    Stenzinger, Albrecht
    Steindorf, Karen
    Delorme, Stefan
    Schlemmer, Heinz-Peter
    Riethdorf, Sabine
    van Schaik, Ron
    Pantel, Klaus
    Siveke, Jens
    Seufferlein, Thomas
    Jaeger, Dirk
    Haefeli, Walter E.
    Trumpp, Andreas
    Springfeld, Christoph
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (12): : 2483 - 2493
  • [23] Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study
    Atkins, Michael B.
    Ravaud, Alain
    Gravis, Gwenaelle
    Drosik, Kazimierz
    Demkow, Tomasz
    Tomczak, Piotr
    Kracht, Karolyn
    Puhlmann, Markus
    Weinreich, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Li, Xingya
    Huang, Siyuan
    Wu, Jingxun
    Li, Yibin
    Chang, Baoping
    Hu, Sheng
    Yang, Shujun
    Xu, June
    Van, Hardy
    Zhi, Lihua
    Xia, Yue
    Yang, Fei
    Xia, Yi
    Kong, Paul
    Dong, Wei
    Xu, Ting
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] A phase II, multicenter, open-label trial to evaluate the safety and efficacy of ISU303 (Agalsidase beta) in patients with Fabry disease
    Hwang, Soojin
    Lee, Beom Hee
    Kim, Woo-Shik
    Kim, Dae-Seong
    Cheon, Chong Kun
    Lee, Chang Hwa
    Choi, Yunha
    Choi, Jin-Ho
    Kim, Ja Hye
    Yoo, Han-Wook
    MEDICINE, 2022, 101 (37) : E30345
  • [26] A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.
    Kang, Hyunseok
    Ho, Alan Loh
    Muzaffar, Jameel
    Bowles, Daniel W.
    Kim, Sung-Bae
    Ahn, Myung-Ju
    Hanna, Glenn J.
    Worden, Francis P.
    Yun, Tak
    Norton, Steven
    Sankar, Neil
    Keam, Bhumsuk
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
    Sherman, E.
    Lee, J. L.
    Debruyne, P. R.
    Keam, B.
    Shin, S. J.
    Gramza, A.
    Caro, I.
    Amin, R.
    Shah, K.
    Yan, Y.
    Huddart, R.
    Powles, T.
    ESMO OPEN, 2023, 8 (02)
  • [28] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [29] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika P.
    Mathews, Cara Amanda
    Chu, Christina
    Diamond, Jennifer Robinson
    Hays, John L.
    Arend, Rebecca Christian
    Cristofanilli, Massimo
    Jewell, Andrea
    Reichmann, William
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Richardson, Debra L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.
    Gutierrez, Martin
    Subbiah, Vivek
    Nemunaitis, John J.
    Mettu, Niharika B.
    Papadopoulos, Kyriakos P.
    Barve, Minal A.
    Feliz, Luis
    Lihou, Christine Francis
    Tian, Chenwei
    Ji, Tao
    Silverman, Ian M.
    Chugh, Rashmi
    Saleh, Mansoor N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345